{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:51:15Z","timestamp":1777701075776,"version":"3.51.4"},"reference-count":34,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.7133","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T22:19:26Z","timestamp":1475273966000},"page":"2759-2764","source":"Crossref","is-referenced-by-count":24,"title":["Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention"],"prefix":"10.2169","volume":"55","author":[{"given":"Takahiro","family":"Masuda","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyochika","family":"Okabe","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Takeda","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Saito","sequence":"additional","affiliation":[{"name":"Kawashima Naika Clinic, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuji","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Nasu Minami Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Nasu Minami Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Akimoto","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Muto","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nagata","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tsai YC, Tsai JC, Chen SC, et al. Association of fluid overload with kidney disease progression in advanced CKD: a prospective cohort study. Am J Kidney Dis 63: 68-75, 2014.","DOI":"10.1053\/j.ajkd.2013.06.011"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tsai YC, Chiu YW, Tsai JC, et al. Association of fluid overload with cardiovascular morbidity and all-cause mortality in stages 4 and 5 CKD. Clin J Am Soc Nephrol 10: 39-46, 2015.","DOI":"10.2215\/CJN.03610414"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292: 288-294, 2000.","DOI":"10.1016\/S0022-3565(24)35289-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cleland JG, Coletta A, Witte K. Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med 119: S26-S36, 2006.","DOI":"10.1016\/j.amjmed.2006.09.014"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: time for a new approach? Circ Heart Fail 7: 531-535, 2014.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000828"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 64: 1772-1779, 2003.","DOI":"10.1046\/j.1523-1755.2003.00273.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Soderberg M, Hahn RG, Cederholm T. Bioelectric impedance analysis of acute body water changes in congestive heart failure. Scand J Clin Lab Invest 61: 89-94, 2001.","DOI":"10.1080\/00365510151097520"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ng Kam Chuen MJ, Lip GY, Macfadyen RJ. Performing repeated noninvasive bedside measures of volume response to intravenous furosemide in acute pulmonary edema: a feasibility assessment. Cardiovasc Ther 27: 89-95, 2009.","DOI":"10.1111\/j.1755-5922.2009.00080.x"},{"key":"9","unstructured":"9. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860-867, 1998."},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107: 2690-2696, 2003.","DOI":"10.1161\/01.CIR.0000070422.41439.04"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol 45: 979-987, 2010.","DOI":"10.1007\/s00535-010-0240-6"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Matsue Y, Suzuki M, Nagahori W, et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. Cardiovasc Drugs Ther 28: 73-77, 2014.","DOI":"10.1007\/s10557-013-6491-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sato E, Nakamura T, Amaha M, et al. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int Heart J 55: 533-538, 2014.","DOI":"10.1536\/ihj.14-190"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tanaka A, Katsuno T, Ozaki T, et al. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol 70: 217-223, 2015.","DOI":"10.1080\/AC.70.2.3073514"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yamazaki T, Morishita Y, Yoshida N, et al. Successful treatment with tolvaptan to control blood volume and hyponatremia in a chronic kidney disease patient. CEN Case Rep 1: 82-85, 2012.","DOI":"10.1007\/s13730-012-0018-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shimizu M, Ishikawa S, Yachi Y, et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol 29: 915-917, 2014.","DOI":"10.1007\/s00467-013-2687-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 61: 169-174, 2013.","DOI":"10.1016\/j.jjcc.2012.08.020"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shirakabe A, Hata N, Yamamoto M, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 78: 911-921, 2014.","DOI":"10.1253\/circj.CJ-13-1255"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol 17: 834-838, 2013.","DOI":"10.1007\/s10157-013-0788-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sartorio A, Malavolti M, Agosti F, et al. Body water distribution in severe obesity and its assessment from eight-polar bioelectrical impedance analysis. Eur J Clin Nutr 59: 155-160, 2005.","DOI":"10.1038\/sj.ejcn.1602049"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Saito O, Saito T, Ueno K, et al. Comparison between serum free triiodothyronine levels and body fluid distribution in hemodialysis patients. Clin Exp Nephrol 16: 952-958, 2012.","DOI":"10.1007\/s10157-012-0648-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. McCafferty K, Fan S, Davenport A. Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients. Kidney Int 85: 151-157, 2014.","DOI":"10.1038\/ki.2013.273"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Davies SJ, Davenport A. The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney Int 86: 489-496, 2014.","DOI":"10.1038\/ki.2014.207"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Rascher W, Tulassay T, Lang RE. Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure. Lancet 2: 303-305, 1985.","DOI":"10.1016\/S0140-6736(85)90351-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lieberman JS, Parra L, Newton L, Scandling JD, Loon N, Myers BD. Atrial natriuretic peptide and response to changing plasma volume in diabetic nephropathy. Diabetes 40: 893-901, 1991.","DOI":"10.2337\/diab.40.7.893"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R. Fluid balance and acute kidney injury. Nat Rev Nephrol 6: 107-115, 2010.","DOI":"10.1038\/nrneph.2009.213"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Raimann JG, Zhu F, Wang J, et al. Comparison of fluid volume estimates in chronic hemodialysis patients by bioimpedance, direct isotopic, and dilution methods. Kidney Int 85: 898-908, 2014.","DOI":"10.1038\/ki.2013.358"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Hung SC, Kuo KL, Peng CH, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int 85: 703-709, 2014.","DOI":"10.1038\/ki.2013.336"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Masuda T, Fu Y, Eguchi A, et al. Dipeptidyl peptidase IV inhibitor lowers PPARgamma agonist-induced body weight gain by affecting food intake, fat mass, and beige\/brown fat but not fluid retention. Am J Physiol Endocrinol Metab 306: E388-E398, 2014.","DOI":"10.1152\/ajpendo.00124.2013"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Morishita Y, Kubo K, Haga Y, et al. Skeletal muscle loss is negatively associated with single-pool Kt\/V and dialysis duration in hemodialysis patients. Ther Apher Dial 18: 612-617, 2014.","DOI":"10.1111\/1744-9987.12174"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int 85: 953-961, 2014.","DOI":"10.1038\/ki.2013.350"},{"key":"33","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(88)91851-X","volume":"1","author":"JD Firth","year":"1988","unstructured":"33. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1: 1033-1035, 1988.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290: F273-F278, 2006.","DOI":"10.1152\/ajprenal.00195.2005"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/19\/55_55.7133\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T22:12:30Z","timestamp":1749593550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/19\/55_55.7133\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":34,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.7133","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}